Biologics

Stem Cell Center Network plans to open a new practice in West Palm Beach, Fla. This will be the network's 5th U.S. facility.

Mick Perez-Cruet, MD, is the chief of minimally invasive spine surgery at Beaumont Hospitals in Royal Oak, Mich., and a neurosurgeon at Michigan Head & Spine Institute in Southfield. He also serves as chairman, director and professor of minimally invasive…

The FDA will allow DiscGenics to conduct an investigational new drug study of IDCT.

Asterias Biotherapeutics reported 12-month data for its Phase 1/2a SCiStar study on spinal cord injury treatment.

Nashville-based Tennessee Orthopaedic Alliance is leveraging platelet rich plasma to treat orthopedic injuries.

James Andrews, MD, and his team at Gulf Breeze, Fla.-based Andrews Institute for Orthopaedics and Sports Medicine are turning to stem cells as the next frontier in sports injury treatments, according to Sports Illustrated.

The global orthobiologics market is predicted to reach $6.06 billion by 2022, growing at a compounded annual rate of 5.4 percent.

DiscGenics closed a Series B financing round.

Columbia-based University of Missouri School of Medicine researchers studied bone marrow aspirate concentrate's impact on knee joint transplant outcomes.

Vail-Summit Orthopaedics will offer platelet-rich plasma and stem cell injections at its Colorado-based locations in Edwards, Frisco and Vail.